PROGNOSTIC VALUE OF PS2 AND CATHEPSIN-D IN 710 HUMAN PRIMARY BREAST-TUMORS - MULTIVARIATE-ANALYSIS

被引:110
作者
FOEKENS, JA
VANPUTTEN, WLJ
PORTENGEN, H
DEKONING, HYWCM
THIRION, B
ALEXIEVAFIGUSCH, J
KLIJN, JGM
机构
[1] DR DANIEL DEN HOED CANC CTR, DEPT STAT, ROTTERDAM, NETHERLANDS
[2] CIS BIO INT, GIF SUR YVETTE, FRANCE
关键词
D O I
10.1200/JCO.1993.11.5.899
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Evaluation of the prognostic value of cytosolic PS2 (pS2 protein) and cathepsin D in a large series of breast cancer patients by multivariate analysis taking into account steroid receptors and conventional prognostic factors. Patients and Methods: Prognostic factors were analyzed in 710 primary breast cancers (median follow-up, 4 years). PS2 and cathepsin D were measured by radiometric immunoassays. Estrogen receptor (ER) and progesterone receptor (PgR) status were assessed by radioligand binding assays and multiple-point Scatchard analysis. Results: The best cutoff point for PS2 to discriminate between positive (61% of the tumors) and negative was 2 ng/mg protein (univariate P value in 5-year relapse-free survival = .003). For cathepsin D, no sensible cutoff point could be chosen, since there was a continuous association between the level of cathepsin D and relapse rate (P = .001). In Cox multivariate analysis, relapse rate decreased with age of premenopausal/perimenopausal patients and with PS2 or steroid receptor positivity, and increased with the size of the tumor, the number of positive lymph nodes, and increasing levels of cathepsin D. In analysis for overall survival, age of both premenopausal/perimenopausal and postmenopausal patients, tumor size, the number of positive lymph nodes, ER/PgR, and PS2 were all independently associated with the rate of death. The level of cathepsin D was positively correlated with the rate of death, but this trend was not statistically significant. Separate Cox multivariate analyses for relapse-free survival in subgroups of patients as defined by nodal status showed that the contribution of PS2 and cathepsin D was the strongest in the node-negative subgroup. Node-negative patients with tumors containing PS2 values ≤ 2 ng/mg protein and cathepsin D values more than 70 pmol/mg protein experienced a 4.5-fold increase in relapse rate as compared with those with PS2 levels greater than 2 ng/mg protein and cathepsin D levels ≤ 30 pmol/mg protein. Conclusion: PS2 and cathepsin D are independent prognostic factors in primary breast cancer and lymph node-negative patients.
引用
收藏
页码:899 / 908
页数:10
相关论文
共 43 条
  • [1] QUALITY-CONTROL OF CATHEPSIN-D MEASUREMENT BY THE EORTC RECEPTOR-STUDY-GROUP
    BENRAAD, TJ
    GEURTSMOESPOT, A
    SALA, M
    PIFFANELLI, A
    ROSS, A
    FOEKENS, JA
    [J]. EUROPEAN JOURNAL OF CANCER, 1992, 28A (01) : 72 - 75
  • [2] Brunk HD., 1972, STAT-US
  • [3] DUFFY MJ, 1991, CLIN CHEM, V37, P101
  • [4] RELATIVE WORTH OF ESTROGEN OR PROGESTERONE-RECEPTOR AND PATHOLOGIC CHARACTERISTICS OF DIFFERENTIATION AS INDICATORS OF PROGNOSIS IN NODE NEGATIVE BREAST-CANCER PATIENTS - FINDINGS FROM NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT PROTOCOL B-06
    FISHER, B
    REDMOND, C
    FISHER, ER
    CAPLAN, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (07) : 1076 - 1087
  • [5] FOEKENS JA, 1991, J CLIN IMMUNOASSAY, V14, P184
  • [6] FOEKENS JA, 1989, CANCER RES, V49, P5823
  • [7] FOEKENS JA, 1989, CANCER RES, V49, P7002
  • [8] FOEKENS JA, 1990, CANCER RES, V50, P3832
  • [9] PROGNOSTIC VALUE OF PS2 PROTEIN AND RECEPTORS FOR EPIDERMAL GROWTH-FACTOR (EGF-R), INSULIN-LIKE GROWTH FACTOR-I (IGF-1-R) AND SOMATOSTATIN (SS-R) IN PATIENTS WITH BREAST AND OVARIAN-CANCER
    FOEKENS, JA
    VANPUTTEN, WLJ
    PORTENGEN, H
    RODENBURG, CJ
    REUBI, JC
    BERNS, PMJJ
    HENZENLOGMANS, SC
    VANDERBURG, MEL
    ALEXIEVAFIGUSCH, J
    KLIJN, JGM
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1990, 37 (06) : 815 - 821
  • [10] RELATIONSHIP BETWEEN CATHEPSIN-D, UROKINASE, AND PLASMINOGEN-ACTIVATOR INHIBITORS IN MALIGNANT VS BENIGN BREAST-TUMORS
    FOUCRE, D
    BOUCHET, C
    HACENE, K
    POURREAUSCHNEIDER, N
    GENTILE, A
    MARTIN, PM
    DESPLACES, A
    OGLOBINE, J
    [J]. BRITISH JOURNAL OF CANCER, 1991, 64 (05) : 926 - 932